Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4774320 | 0.98 | SIGMAR1 (0.57) | SIGMAR1SLC18A3P2RY14HTR2CQDPR | |
| SCHEMBL31386222 | 0.89 | JAK3 (0.59) | JAK3 | |
| SCHEMBL2321634 | 0.86 | TSHR (0.57) | DRD1TP53TSHR | |
| SCHEMBL901207 | 0.86 | TSHR (0.57) | DRD1TP53TSHR | |
| SCHEMBL901209 | 0.86 | TSHR (0.57) | DRD1TP53TSHR | |
| SCHEMBL18553793 | 0.84 | SLC18A3 (0.63) | SIGMAR1SLC18A3P2RY14HTR2CQDPR | |
| Hydrochloric Acid SCHEMBL4290507 | 0.84 | TSHR (0.55) | DRD1TP53TSHR | |
| SCHEMBL1285399 | 0.83 | QDPR (0.50) | SIGMAR1SLC18A3P2RY14HTR2CQDPR | |
| SCHEMBL7263062 | 0.83 | SLC18A3 (0.52) | SIGMAR1SLC18A3P2RY14HTR2CQDPR | |
| SCHEMBL1758181 | 0.83 | CYP2C9 (0.55) | SIGMAR1SLC18A3HTR2CQDPRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116497411-A | Cyanide-free alkaline silver plating electroplating solution and preparation and application thereof | 上海电力大学 | 2023-07-28 | — | — | CN | claimed |
| CN-112225895-A | Flame-retardant aromatic polyoxadiazole polymer and preparation method thereof | 欧阳杰 | 2021-01-15 | — | — | CN | claimed |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | claimed |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116497411-A | Cyanide-free alkaline silver plating electroplating solution and preparation and application thereof | 上海电力大学 | 2023-07-28 | — | — | CN | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2021-09-09 | — | — | US | disclosed |
| EP-1254124-A1 | DIPEPTIDE NITRILE CATHPSIN K INHIBITORS | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| CN-1333766-A | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1097753-A | 5-membered heterocycles, preparation method and the pharmaceutical composition that contains these compounds | THOMAE GMBH DR K (DE) | 1995-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | SIGMAR1 3522/4885SLC18A3 4361/4885P2RY14 3166/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | SIGMAR1 1047/4885SLC18A3 2226/4885P2RY14 602/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | SIGMAR1 3522/4885SLC18A3 4361/4885P2RY14 3166/4885 |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | SIGMAR1 3335/4885SLC18A3 4483/4885P2RY14 3440/4885 |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | PDXK, MAP4K2, PLK2 | SIGMAR1 3625/4885SLC18A3 4351/4885P2RY14 1055/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | SIGMAR1 3366/4885SLC18A3 4472/4885P2RY14 3344/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | SIGMAR1 2452/4885SLC18A3 4536/4885P2RY14 3135/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | SIGMAR1 3312/4885SLC18A3 4480/4885P2RY14 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.